January 2022 in “Journal of Drug Delivery and Therapeutics” This study reported that all ten COVID-19 patients experienced early onset of Telogen effluvium within three months of infection, after recovering without hospitalization.
25 citations
,
December 2021 in “Journal of Medical Virology” This systematic review reports that acute telogen effluvium may occur as a stress-induced hair loss following COVID-19 recovery, with most patients experiencing hair regrowth over time.
39 citations
,
August 2021 in “JAAD International” This study found that telogen effluvium and trichodynia are common in patients after COVID-19, and their severity may be influenced by the severity of the COVID-19 infection.
32 citations
,
July 2021 in “Journal of The American Academy of Dermatology” This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.
18 citations
,
April 2021 in “Experimental Dermatology” This study in Italy observed telogen effluvium and trichodynia as common hair-related complications following COVID-19 infection, raising questions about underlying hair follicle biology and potential receptor involvement.
3 citations
,
April 2021 in “Revista da Sociedade Portuguesa de Dermatologia e Venereologia” This study reports that a third of patients with SARS-CoV-2 infection developed acute telogen effluvium within three weeks, highlighting a notable pattern of early hair loss following COVID-19.
6 citations
,
January 2021 in “Journal of Cosmetic Dermatology” This article discusses the potential association between stress, poor sleep, and telogen effluvium during the COVID-19 pandemic, highlighting the possible role of substance P, but reports no new clinical results.
35 citations
,
November 2020 in “Dermatologic Therapy” This case series reports telogen effluvium in three patients following severe Sars-Cov-2 infection and suggests a potential association that merits further investigation.
737 citations
,
August 2020 in “Journal of Infection” This study found that most patients hospitalized for COVID-19 experienced persistent symptoms over 100 days post-admission, with no significant difference in symptoms between those treated in regular wards and intensive care units.
